Alnylam Drug Moves Forward at FDA
- Posted by ISPE Boston
- On September 14, 2023
RNAi therapeutics company Alnylam Pharmaceuticals welcomed the positive outcome of the FDA advisory committee meeting. On Wednesday the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:3 that the benefits of RNAi therapeutic patisiran outweigh its risks for the treatment of the cardiomyopathy of ATTR amyloidosis. The CRDAC provides the FDA with independent, expert advice and recommendations […]
Read More